ScoreWhy is Xilio Therapeutics, Inc. ?
1
With a growth in Net Sales of 242.98%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -13.33 MM
- NET PROFIT(HY) Higher at USD -29.06 MM
- DEBT-EQUITY RATIO (HY) Lowest at -1,612.46 %
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -33.87%, its profits have risen by 22.4%
3
Below par performance in long term as well as near term
- Along with generating -33.87% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Xilio Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xilio Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Xilio Therapeutics, Inc.
-33.87%
-0.21
166.87%
S&P 500
12.83%
0.64
20.14%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
100.00%
EBIT Growth (5y)
3.25%
EBIT to Interest (avg)
-64.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.21
Sales to Capital Employed (avg)
0.64
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
69.13%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.39
EV to EBIT
0.91
EV to EBITDA
0.94
EV to Capital Employed
0.67
EV to Sales
-5.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
73.83%
ROE (Latest)
-507.61%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -13.33 MM
NET PROFIT(HY)
Higher at USD -29.06 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -1,612.46 %
RAW MATERIAL COST(Y)
Fallen by -17.69% (YoY
NET SALES(Q)
Highest at USD 8.08 MM
OPERATING PROFIT MARGIN(Q)
Highest at -173 %
EPS(Q)
Highest at USD -0.16
-4What is not working for the Company
ROCE(HY)
Lowest at -277.74%
PRE-TAX PROFIT(Q)
Lowest at USD -15.79 MM
NET PROFIT(Q)
Lowest at USD -15.79 MM
Here's what is working for Xilio Therapeutics, Inc.
Net Sales
At USD 8.08 MM has Grown at 242.98%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -13.33 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at -1,612.46 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at USD 8.08 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -173 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD -0.16
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -17.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Xilio Therapeutics, Inc.
Pre-Tax Profit
Lowest at USD -15.79 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -15.79 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
